Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alvotech Warrant (ALVOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ALVOW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -0.17% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.19 | 52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 |
52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.42% | Operating Margin (TTM) 7.97% |
Management Effectiveness
Return on Assets (TTM) 7.02% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 100126591 |
Shares Outstanding - | Shares Floating 100126591 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Alvotech Warrant
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on the development and manufacture of biosimilar medicines. The warrant is related to the company's business combination with Oaktree Acquisition Corp. II, completed in June 2022, resulting in Alvotech becoming a publicly traded company.
Core Business Areas
- Biosimilar Development: Development and commercialization of biosimilar versions of major biologic drugs across therapeutic areas like immunology, ophthalmology, and oncology.
- Manufacturing: Operates a state-of-the-art biomanufacturing facility to produce biosimilar products.
- Commercialization: Partners with global pharmaceutical companies to commercialize its biosimilar products worldwide.
Leadership and Structure
Robert Wessman is the founder and Chairman. The company has a management team with expertise in biosimilar development, manufacturing, and commercialization. Organizational structure includes R&D, manufacturing, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- AVT02 (biosimilar Humira): Alvotech's lead biosimilar product, a biosimilar to Humira (adalimumab), used to treat autoimmune diseases. Competitors include Amgen (AMGN) with Amjevita, Sandoz with Hyrimoz, and Boehringer Ingelheim with Cyltezo. Market share data varies by region; expecting a global market share between 5-15% within the next 5 years. US revenues are expected to increase dramatically as patents expire for branded products.
- AVT04 (biosimilar Stelara): Alvotech's biosimilar to Stelara, used to treat autoimmune diseases. Competitors include Amgen (AMGN) , Biogen (BIIB). Expected a market share between 5-15% within the next 5 years, depending on approval and commercialization success.
- Other Biosimilars: Alvotech is developing biosimilars for other major biologic drugs in various therapeutic areas. No specific market share data is publicly available yet.
Market Dynamics
Industry Overview
The biosimilar market is growing rapidly due to increasing healthcare costs and the expiration of patents on originator biologic drugs. Regulatory pathways for biosimilar approval are becoming more established, facilitating market entry.
Positioning
Alvotech aims to be a leading global player in the biosimilar market by developing and manufacturing high-quality, cost-effective biosimilar products. It focuses on complex biosimilars, differentiating itself from competitors producing easier-to-manufacture biosimilars.
Total Addressable Market (TAM)
The global biosimilar market is expected to reach hundreds of billions of dollars in the coming years. Alvotech is positioned to capture a significant share of this TAM through its pipeline of biosimilar products.
Upturn SWOT Analysis
Strengths
- Strong biosimilar development capabilities
- State-of-the-art biomanufacturing facility
- Strategic partnerships for global commercialization
- Focus on complex biosimilars
- Experienced management team
Weaknesses
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Dependence on partnerships for commercialization
- High R&D costs associated with biosimilar development
- Regulatory and legal challenges related to biosimilar approvals
- Heavy debt
Opportunities
- Growing biosimilar market driven by patent expirations and cost pressures
- Expanding into new therapeutic areas and geographic markets
- Potential for strategic acquisitions or collaborations
- Increasing acceptance of biosimilars by healthcare providers and patients
- Government initiatives to promote biosimilar use
Threats
- Competition from established pharmaceutical companies and other biosimilar developers
- Pricing pressures and reimbursement challenges
- Regulatory hurdles and potential delays in biosimilar approvals
- Intellectual property disputes and patent litigation
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- AMGN
- BIIB
- VTRS
- SNY
Competitive Landscape
Alvotech faces intense competition from established pharmaceutical companies and other biosimilar developers. Its advantage lies in its focus on complex biosimilars and its state-of-the-art manufacturing facility.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage in the public market.
Future Projections: Future growth is projected to be driven by the successful launch and commercialization of its biosimilar products, particularly AVT02 and AVT04. Analyst estimates vary depending on market penetration and pricing assumptions.
Recent Initiatives: Recent initiatives include securing regulatory approvals for AVT02 in various markets, advancing the development of its biosimilar pipeline, and expanding its commercial partnerships.
Summary
Alvotech is a biosimilar company with potential in a growing market. Its strength lies in its biosimilar development capabilities and manufacturing prowess. However, it faces challenges relating to the heavy debts and intense competition. The company needs to commercialize its products successfully and secure its financial position to solidify its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.